Headlines about MiMedx Group (NASDAQ:MDXG) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MiMedx Group earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media headlines about the medical equipment provider an impact score of 44.0147018215591 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Two Independent Poster Abstracts Highlighting The Clinical Efficacy of MiMedx Allografts are Recognized at The 2017 … – Markets Insider (markets.businessinsider.com)
- Understanding Basic Stock Data: MiMedx Group, Inc. (MDXG) – Market Movers (financialqz.com)
- Two Independent Poster Abstracts Highlighting The Clinical Efficacy of MiMedx Allografts are Recognized at The 2017 Desert Foot Conference (finance.yahoo.com)
- MiMedx Group (MDXG) and Sientra (SIEN) Financial Review (americanbankingnews.com)
- MiMedx Group (MDXG) Sees Exceeding Top End of Q4 Revenue Guidance (streetinsider.com)
MiMedx Group (MDXG) opened at $11.45 on Thursday. The firm has a market capitalization of $1,288.01, a P/E ratio of 55.24, a price-to-earnings-growth ratio of 2.76 and a beta of 0.87. MiMedx Group has a 12-month low of $7.64 and a 12-month high of $17.47.
MiMedx Group declared that its Board of Directors has authorized a share repurchase program on Monday, October 9th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
Several research firms recently issued reports on MDXG. Needham & Company LLC upped their target price on MiMedx Group from $20.00 to $21.00 and gave the stock a “strong-buy” rating in a report on Tuesday, September 5th. Piper Jaffray Companies reiterated a “buy” rating and set a $18.00 target price on shares of MiMedx Group in a report on Sunday, August 20th. BidaskClub upgraded MiMedx Group from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. Finally, Zacks Investment Research downgraded MiMedx Group from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. MiMedx Group has an average rating of “Hold” and a consensus price target of $15.40.
About MiMedx Group
MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
Receive News & Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.